<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626652</url>
  </required_header>
  <id_info>
    <org_study_id>CJI-201</org_study_id>
    <nct_id>NCT00626652</nct_id>
  </id_info>
  <brief_title>Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation</brief_title>
  <acronym>RESTORATION</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Effects of K201 Injection, 2 mg/mL on the Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequel Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequel Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of K201 on sinus rhythm restoration, symptom score, various&#xD;
      cardiovascular parameters, and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of sinus rhythm</measure>
    <time_frame>24hrs</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K201 Injection</intervention_name>
    <description>single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic atrial fibrillation&#xD;
&#xD;
          -  Atrial fibrillation documented by ECG&#xD;
&#xD;
          -  Adherence to local clinical standards or the ACC/AHA/ESC practice guidelines for&#xD;
             atrial fibrillation regarding thrombo-embolic event prevention and treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic blood pressure &lt;100 mmHg&#xD;
&#xD;
          -  Heart rate &lt;50 bpm&#xD;
&#xD;
          -  Temperature &gt;38Â°C&#xD;
&#xD;
          -  QT or QTcB &gt;440 ms&#xD;
&#xD;
          -  QRS &gt;140 ms&#xD;
&#xD;
          -  Paced atrial or ventricular rhythm on ECG&#xD;
&#xD;
          -  Serum potassium &lt;3.5 meq/L&#xD;
&#xD;
          -  History of receiving another intravenous Class I or Class III antiarrhythmic drug&#xD;
             within 3 days of randomization&#xD;
&#xD;
          -  History of amiodarone in last 6 months.&#xD;
&#xD;
          -  Clinical evidence of acute coronary syndrome&#xD;
&#xD;
          -  Acute pulmonary edema or embolism&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Acute pericarditis&#xD;
&#xD;
          -  History of failed electrical cardioversion at any time&#xD;
&#xD;
          -  History of torsades des pointes&#xD;
&#xD;
          -  History of familial long QT interval syndrome&#xD;
&#xD;
          -  History of ventricular tachycardia requiring drug or device therapy&#xD;
&#xD;
          -  History of NYHA Heart Failure Class 3 or 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Pavlovich Golitsyn, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Cardiologic Scientific and Manufacturing Complex of Roszdrav, Institute of Cardiology n.a. A.L.Myasnikov, Department of clinical electrophysiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amos Katz, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barzilai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>February 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>January 7, 2010</last_update_submitted>
  <last_update_submitted_qc>January 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Howard C. Dittrich, MD; Chief Medical Officer</name_title>
    <organization>Sequel Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

